Loading provider…
Loading provider…
Hematology & Oncology Physician in Camden, NJ
NPI: 1285725267Primary Practice Location
COOPER UNIVERSITY HOSPITAL
1 Cooper Plz, Camden, NJ
Primary Employer
Cmc Department of Medicine Group PA
cooperhealth.org
HQ Phone
Get MD Robert's Phone Numberphone_androidMobile
Get MD Robert's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
NJ State Medical License
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Authors: Francisco Esteva, Will Williams, Abenaa Brewster, Alejandra Perez
Publication Date: 2013-05-24
Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy.
Authors: Cardonick, Elyce, Gilmandyar, Dzhamala, Somer, Robert A
Journal: Obstet Gynecol
Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
Authors: Alexandre Hageboutros, Tracey Evans
Publication Date: 2012-02-08
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, OTHER: Data Collection
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, DRUG: Cisplatin, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, OTHER: Survey Administration, DRUG: Atezolizumab, DRUG: Gemcitabine, DRUG: Fluorouracil, PROCEDURE: Computed Tomography, DRUG: Mitomycin, PROCEDURE: Transurethral Resection of Bladder Tumor, PROCEDURE: Biopsy of Bladder, PROCEDURE: Cystoscopy
Lead Sponsor: MacroGenics
Intervention / Treatment: BIOLOGICAL: Trastuzumab, DRUG: Physician's choice of chemotherapy., BIOLOGICAL: Margetuximab